patient
treat
standard
fcr
regimen
peter
maccallum
cancer
centr
march
june
identifi
medic
manag
databas
pjp
case
time
also
identifi
electron
databas
pjp
prophylaxi
administ
accord
physician
prefer
studi
period
institut
guidelin
recommend
pjp
prophylaxi
oral
patient
lymphoma
evid
impair
immun
due
diseas
cumul
exposur
system
anticanc
therapi
eg
alemtuzumab
therapi
patient
receiv
corticosteroid
daili
dose
equival
greater
thana
minimum
averag
dose
mg
prednisolon
month
pneumocysti
jirovecii
pneumonia
defin
presenc
radiolog
confirm
pulmonari
infiltr
identif
p
jirovecii
respiratori
tract
sampl
bronchoalveolar
lavag
bal
induc
sputum
polymeras
chain
reaction
pcr
absenc
pathogen
caus
diffus
pulmonari
infiltr
investig
perform
bal
accord
standardis
protocol
includ
bacteri
fungal
cultur
viral
pcr
techniqu
fungal
infect
tabl
semiquantit
pcr
target
p
jirovecii
major
surfac
glycoprotein
gene
perform
maximum
cycl
detect
accord
previous
publish
method
radiolog
investig
includ
ct
andor
fdg
petct
imag
median
durat
fcr
complet
rang
month
differenti
infect
rate
pjp
calcul
patient
receiv
pjp
prophylaxi
develop
pjp
fcr
chemotherapi
ii
develop
pjp
complet
fcr
chemotherapi
incid
pjp
follow
fcr
calcul
per
patient
treat
median
fcr
rang
cycl
underli
condit
includ
chronic
lymphocyt
leukaemia
cll
n
mantl
cell
lymphoma
n
follicular
lymphoma
n
macroglobulinaemia
n
indol
lymphoma
n
patient
receiv
prior
chemotherapi
regimen
includ
chlorambucil
n
autolog
stem
cell
transplant
n
fcfcr
n
cyclophosphamid
vincristin
doxorubicin
dexamethason
n
rituximab
cyclophosphamid
doxorubicin
vincristin
prednisolon
n
unknown
n
patient
receiv
pjp
prophylaxi
n
dapson
n
month
follow
fcr
prophylaxi
continu
complet
fcr
ie
beyond
month
patient
median
rang
day
eight
pjp
case
identifi
case
cluster
epidemiolog
clinic
find
outcom
summaris
tabl
case
new
pulmonari
infiltr
identifi
imag
addit
elev
protein
crp
rang
mgl
normal
mgl
document
patient
consist
infect
process
follow
treatment
crp
normalis
six
patient
test
repeat
pneumocysti
jirovecii
pneumonia
diagnos
fcr
treatment
one
patient
cycl
median
six
rang
month
complet
fcr
treatment
remain
seven
patient
six
patient
receiv
prior
chemotherapi
regimen
patient
develop
pjp
month
follow
fcr
recent
receiv
investig
drug
patient
episod
occur
patient
receiv
concurr
pjp
prophylaxi
patient
receiv
pjp
prophylaxi
one
binomi
confid
interv
ci
seven
ci
develop
pjp
respect
incid
pjp
follow
fcr
chemotherapi
per
cycl
threshold
p
jirovecii
detect
pcr
span
median
six
patient
addit
molecular
bal
result
consid
repres
colonis
aspergillu
spp
cytomegaloviru
inconsist
clinic
present
herp
simplex
viru
staphylococcu
aureu
moraxella
catarrhali
tabl
set
fever
elev
inflammatori
marker
new
onset
pulmonari
infiltr
altern
chronic
process
consid
unlik
two
patient
present
pyrexia
unknown
origin
puo
bilater
pulmonari
infiltr
identifi
fdg
petct
median
lymphocyt
count
time
pjp
diagnosi
six
patient
test
rang
compar
median
count
test
nine
month
follow
fcr
three
patient
test
rang
seven
patient
complet
respons
pjp
treatment
one
patient
die
respiratori
failur
find
suggest
risk
pjp
follow
fcr
may
higher
previous
appreci
three
randomis
trial
investig
fcr
lymphoid
malign
pjp
prophylaxi
mandat
fcr
month
follow
fcr
presenc
lymphopenia
beyond
day
therefor
increas
risk
pjp
treatment
report
extend
risk
pjp
follow
fcr
similarli
report
pjp
identifi
infrequ
first
month
remiss
previous
treat
untreat
patient
note
studi
conduct
routin
use
pcr
diagnosi
pjp
avail
newer
diagnost
tool
improv
sensit
detect
pjp
part
explain
higher
rate
observ
studi
convent
quantit
pcr
sensit
specif
identifi
pneumocysti
respiratori
secret
unabl
distinguish
infect
colonis
pneumocysti
colonis
describ
patient
haematolog
malign
although
rate
unknown
quantit
pcr
propos
one
method
differenti
infect
colonis
one
studi
show
copi
number
significantli
higher
definit
probabl
pjp
patient
colonis
patient
although
clinic
relev
valu
valid
low
median
cycl
threshold
p
jirovecii
dna
detect
henc
high
organ
burden
cohort
suggest
infect
rather
colonis
presenc
respiratori
symptom
compat
radiolog
chang
elev
inflammatori
marker
respons
treatment
favour
infect
colonis
fdg
pet
also
emerg
tool
identif
otherwis
occult
infect
neutropen
patient
prolong
unexplain
fever
howev
contribut
fdg
pet
diagnosi
pjp
previous
describ
three
case
report
cohort
bilater
fdg
uptak
lung
seen
patient
pjp
underw
fdg
pet
includ
two
patient
puo
normal
chest
ct
find
suggest
util
fdg
pet
earli
pjp
detect
fludarabin
cyclophosphamid
rituximab
induc
profound
sustain
patient
cll
undergo
fcr
median
time
reach
lymphocyt
count
six
month
respect
correl
risk
late
infect
first
year
remiss
fcr
second
year
patient
infect
human
immunodefici
viru
hiv
strong
associ
count
pjp
risk
monitor
count
also
use
identifi
immunocompromis
patient
may
risk
pjp
cohort
count
measur
time
pjp
diagnosi
five
six
patient
valu
interest
also
recoveri
count
within
month
follow
fcr
three
patient
observ
suggest
evalu
role
immun
marker
risk
stratif
warrant
confirm
direct
causal
relationship
possibl
risk
factor
develop
pjp
difficult
particularli
relev
heavili
pretreat
patient
consecut
chemotherapi
regimen
may
contribut
addit
immun
suppress
effect
may
explain
predomin
pjp
pretreat
patient
compar
patient
seri
howev
pjp
report
associ
chemotherapi
regimen
fcr
recent
administ
chemotherapi
major
patient
therefor
consid
exert
greatest
risk
limit
studi
retrospect
interpret
diagnost
result
pulmonari
toxic
import
differenti
diagnosi
pulmonari
infiltr
pulmonari
toxic
report
singl
us
centr
treat
patient
onset
usual
within
week
follow
fcr
howev
put
phenomenon
reproduc
centr
larger
prospect
studi
even
accept
possibl
caus
pneumon
would
explain
later
present
observ
seri
altern
infect
diagnosi
also
consid
unlik
given
extens
investig
bal
specimen
absenc
detect
cytomegaloviru
blood
pcr
typic
radiolog
chang
invas
fungal
infect
bacteri
pneumonia
suggest
addit
organ
unlik
clinic
signific
final
pjp
prophylaxi
institut
accord
physician
discret
bia
may
impact
calcul
rate
result
studi
indic
risk
develop
pjp
follow
fcr
treatment
lymphoid
malign
previous
underappreci
newer
sensit
diagnost
modal
avail
identifi
pjp
potenti
caus
respiratori
symptom
puo
studi
requir
molecular
techniqu
reliabl
use
identifi
patient
pneumocysti
infect
distinct
colonis
similarli
evalu
role
monitor
warrant
quantifi
risk
diseas
develop
guid
durat
prophylaxi
threshold
valid
popul
suggest
use
primari
pjp
prophylaxi
fcr
treatment
cycl
year
follow
fcr
complet
particularli
relev
pretreat
patient
ma
antifung
advisori
board
gilead
scienc
inc
merck
pfizer
australia
receiv
fund
form
unit
grant
gilead
scienc
inc
merck
pfizer
australia
pfizer
intern
jf
receiv
honoraria
travel
support
speaker
bureau
roch
ct
receiv
honoraria
travel
support
roch
sl
research
offic
project
fund
unrestrict
grant
roch
speaker
fee
paid
direct
hospit
gmh
bwt
kat
ljw
declar
conflict
interest
